(VIN.C) Feb. 16, 2017 – In conjunction with its proposed acquisition of MJ BioPharma (announced on Dec. 14, 2016), and as a part of the company’s strategy to develop a lab for research and development products that test and identify specific cannabinoid isolates for targeted therapeutic purposes, Vinergy Resources Ltd. has appointed John Simon to the company’s scientific advisory board.
Mr. Simon has a bachelor of science from the University of Alberta, is a senior member of the American Society for Quality, a certified quality auditor, a registered quality assurance professional in good laboratory practice and maintains regulatory affairs certification through the Regulatory Affairs Professional Society.
Mr. Simon has held various management positions in quality assurance (QA) and regulatory affairs, and has worked as a consultant supporting clients in the medical device, pharmaceutical, biotechnology and natural health product industries since 2004. He has been directly involved in U.S. Food and Drug Administration (FDA) and Health Canada audits of medical device manufacturers, drug manufacturers, testing facilities and clinical sites. He has experience with submissions to the FDA and Health Canada.
Through Mr. Simon’s consultancy practice, he assists companies with both site licences and product licences. He has helped companies obtain, renew and maintain in good standing drug establishment licences, medical device establishment licences, natural and non-prescription site licences, and licences to cultivate and distribute under the marijuana for medical purposes regulations (now under the access to cannabis for medical purposes regulations).
Mr. Simon also works in creating quality systems to support ISO certification for various clients (ISO 17025, ISO 13485 and ISO 9001). Mr. Simon consults to groups in the creation of specifications, batch records and procedures to support the design and development of a variety of products including cosmetics, natural health products, medical devices, biologics, pharmaceuticals and controlled substances.
“With John’s substantial background in QA and regulatory affairs specific to drug development and the cannabis industry, he will be a key asset in driving our cannabis product and technology initiatives,” said Kent Deuters, chief executive officer of MJ Biopharma.
We seek Safe Harbor.Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.